P-BCMA-ALLO1, an allogenic CAR-T targeting BCMA for relapsed/refractory multiple myeloma (RRMM), is manufactured using the piggyBac® DNA Delivery System and the Cas-CLOVERTM gene editing system, which eliminates TCR expression and reduces MHC class I expression to prevent GvHD. This evidence concerns the gene TNFRSF17 and graft versus host disease.